Regulus Therapeutics, Inc. Overview
Company Headquarters: California, US
Founded: 2007
Company Working: Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company engaging in the discovery and development of drugs that target microRNAs to treat a range of diseases in the US and Europe. Its two lead products include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease and RGLS4326, an anti-miR targeting miR-17, which is in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for Hepatitis B virus, NASH, and other infectious diseases.
Strategy
Regulus Therapeutics Inc. focuses on increasing its presence in the NASH biomarkers market. The company also aims to increase its product portfolio by increasing its research & development of the same.
